- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The US Cannot Afford the Price of Expensive Specialty Drugs
Although drug development is expensive, the high prices being charged for some specialty drugs, like Sovaldi, are not required to induce innovation, Len M. Nichols, PhD, wrote Monday for Morning Consult.
director of the Center for Health Policy Research and Ethics
Although drug development is expensive, the high prices being charged for some specialty drugs, like Sovaldi, are not required to induce innovation, Len M. Nichols, PhD, at George Mason University, wrote Monday for Morning Consult.
The high cost of complex drugs, often targeted to small patient populations, are unaffordable for the individual patients and the government. Despite making up just 1% of prescriptions writte, specialty drugs accounted 25% of drug spending in 2013, according to Dr Nichols, with spending on these medications growing faster than for all other drugs. It's estimated that by 2019 specialty drug spend will account for more than half of all drug spending.
"So what price we should pay for specialty drugs? High enough to keep productive R&D investment flowing into a risky and vital industry, but not whatever the successful companies want to charge just because they can," Dr Nichols wrote.
Read the full post at Morning Consult: http://bit.ly/1J0kIFZ
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Higher UTI Risk After Spinal Fusion in Patients With Certain Comorbidities
March 5th 2025A study investigated the incidence of postoperative urinary tract infections (UTIs) in patients undergoing spinal fusion for deformities, finding that patients with more than 12 levels fused had the highest UTI rates.
Read More
